← FDA DRUG APPROVALS

FDA ANDA · ANDA204954

METHYLPHENIDATE HYDROCHLORIDE

Sponsor: QUAGEN

APPLICATION
ANDA204954
TYPE
ANDA
ORIGINAL APPROVAL
2017-01-26
LATEST ACTION
2023-10-13
ROUTE
ORAL
DOSAGE FORM
TABLET, CHEWABLE
MARKETING STATUS
Discontinued

Products

METHYLPHENIDATE HYDROCHLORIDEDiscontinued
METHYLPHENIDATE HYDROCHLORIDE 10MG · TABLET, CHEWABLE · ORAL
METHYLPHENIDATE HYDROCHLORIDEDiscontinued
METHYLPHENIDATE HYDROCHLORIDE 2.5MG · TABLET, CHEWABLE · ORAL
METHYLPHENIDATE HYDROCHLORIDEDiscontinued
METHYLPHENIDATE HYDROCHLORIDE 5MG · TABLET, CHEWABLE · ORAL

Approval history

2023-10-13Labeling · Supplement 4 · standardAP
2021-06-25Labeling · Supplement 3 · standardAP
2017-01-26UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →